

PACE

PROVIDER BULLETIN

November 23, 2010

Propoxyphene (Darvon®, Darvocet®)

Xanodyne Pharmaceuticals is withdrawing propoxyphene.

The FDA recommends that healthcare professionals stop prescribing propoxyphene; contact patients currently taking propoxyphene related products; ask them to discontinue taking the medication and inform patients of the risks and discuss pain management alternatives .

Effective November 30, 2010 Darvon®, Darvocet® and all propoxyphene related products will reject with PACE Reject 055, NCPDP Reject 70 “Drug Not Covered.” This applies to both new and refilled prescriptions.

Propoxyphene will not be reimbursed by any program under the auspices of the Department of Aging (PACE, CRDP, SPBP etc.).

**Questions may be directed to Provider Services
at 1-800-835-4080.**